PROVIDENCE, R.I., July 10,
2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a
biotechnology company developing first-in-class therapeutics to
promote neurogenesis for the potential treatment of CNS illnesses,
today announced their invitation to present at the
4th Annual Oligonucleotides for CNS Summit
on July 10th in Boston, MA.
Justin Fallon, Ph.D., Scientific
Co-Founder and Scientific Advisory Board Chair of Bolden
Therapeutics, will present an update on the development of Bolden's
first-in-class treatment to promote adult hippocampal neurogenesis.
"We are appreciative of the opportunity to present at the
Oligonucleotides for CNS Summit and I am excited to share our
progress with the broader antisense and CNS drug development
communities," said Dr. Fallon. "Adult neurogenesis is a promising
target for the treatment of a wide range of neurological conditions
and neurodegenerative diseases, and we have made significant
achievements towards our goal of developing an antisense candidate
to increase neurogenesis."
Dr. Fallon will present today, Wednesday, July
10th at 2PM in the Hilton Boston Back Bay
in Boston, MA. Interested parties
who are unable to make the presentation may submit inquiries or
request additional information by emailing
info@boldentherapeutics.com.
About Bolden Therapeutics, Inc.
Bolden Therapeutics,
Inc., is a biotechnology company developing first-in-class
therapeutics to promote neurogenesis for the potential treatment of
central nervous system illnesses such as Alzheimer's disease.
Bolden's foundational research originated from two Brown
University research labs in Providence, RI. Bolden
received two 'Golden Tickets' from Biogen, allowing the company to
take residence at LabCentral and providing the company with two
years of sponsored laboratory space within that innovative
ecosystem. Bolden's research facility is currently located at the
Tufts Launchpad | biolabs incubator. Bolden is currently raising
funds to support ongoing in vivo experiments and preclinical
development.
More information about Bolden Therapeutics can be found
at www.boldentherapeutics.com.
About Oligonucleotides for CNS Summit
The
Oligonucleotides for CNS Summit is the only summit centered on the
needs of biotech and pharma specific to CNS oligos. The Summit
consists of three days including 20+ world-class speakers from the
likes of Roche, Ionis, Genentech, Merck, Stoke Therapeutics, and
Janssen. More information about this exciting event can be found at
https://oligonucleotides-cns.com.
View original
content:https://www.prnewswire.com/news-releases/bolden-therapeutics-to-present-at-the-4th-annual-oligonucleotides-for-cns-summit-302193580.html
SOURCE Bolden Therapeutics, Inc.